english.prescrire.org > Spotlight > 100 most recent > Antineoplastic drugs + PPIs: shorter survival

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Antineoplastic drugs + PPIs: shorter survival

 Adverse Effects  What are the main evaluation data on the risk of excess mortality with concomitant exposure to an antineoplastic drug and a proton pump inhibitor? To what extent do these data help in making healthcare decisions?
Full article available for download by subscribers

 ©Prescrire 1 July 2025

Source: "Antineoplastic drugs + PPIs: shorter survival" Prescrire Int 2025; 34 (272): 186-187. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:

"Proton pump inhibitors:
increased mortality"
Prescrire Int 2019;
28 (200): 13-15.
Subscribers only
 
"Overprescription of PPIs:
increased mortality
and morbidity"
Prescrire Int 2025;
34 (271): 164.
Subscribers only

"Proton pump inhibitors:
how to avoid unjustified risks
and how to 'deprescribe'"
Prescrire Int 2021;
30 (228): 186-187.
Subscribers only